Clinical trials: Elderly Immune Senescence
Multiple Myeloma
Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e.
- Trial name
- BVD (NCT01045681)
- Testing
- Bendamustine, Velcade and Dexamethasone
- Where
- 37 sites in France
- Volunteers
- 75 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Sclerosis, Colitis, Ulcerative
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.
- Trial name
- NCT05131971
- Testing
- GSK3888130B
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse…
- Trial name
- NCT00396045
- Testing
- Revlimid (CC-5013)
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- University of Turin, Italy
Influenza Infection
Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer
Influenza vaccination reduces the morbidity and mortality associated with influenza infection in at risk groups including the elderly and individuals with an impaired immune response, but is not totally protective in all…
- Trial name
- GP-INFA (NCT00647465)
- Testing
- vaccine
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Myeloma
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Overall the issue of patients above 65-70 years of age being that it is impossible for most of them to undergo an intensive treatment like autologous stem cell transplant with little prospect of debulking effectively the bone…
- Trial name
- NCT04751877
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Poitiers University Hospital
Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies.
- Trial name
- INVISE (NCT06539338)
- Testing
- INT2104
- Where
- 3 sites in Australia, Spain
- Volunteers
- 10 people
- Sponsor
- Kite, A Gilead Company
Elderly People
Immune Benefits of WGP in Elderly
The aim of this research is to assess the immune enhancing property of food fibers in the elderly population.
- Trial name
- NCT02262091
- Testing
- Food fibers, Maltodextrin, Influenza vaccine (incl. criterion)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Société des Produits Nestlé (SPN)
Hodgkin's Disease, Lymphoma
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is to replace a drug with many side effects, procarbazine, with a new novel drug, vorinostat, in a drug combination for the treatment of patients with diffuse large B-cell lymphoma.
- Trial name
- NCT00667615
- Testing
- rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Type 1 Diabetes Mellitus
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.
- Trial name
- KIBOU-T1D (NCT06791291)
- Testing
- Teplizumab
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Sanofi
Influenza, Orthomyxovirus Infections
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.
- Conditions
- Influenza, Orthomyxovirus Infections, Myxovirus Infection
- Trial name
- NCT00776438
- Testing
- Inactivated, split-virion, influenza vaccine, Inactivated, split-virion influenza vaccine
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Multiple Myeloma at First Relapse
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple…
- Trial name
- I2D IFM2021_03 (NCT04998786)
- Testing
- Ixazomib, Iberdomide, Dexamethasone Oral
- Where
- 21 sites in France
- Volunteers
- 75 people
- Sponsor
- Nantes University Hospital
Lymphoma, Mantle-Cell
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed…
- Trial name
- NCT06136351
- Testing
- Zanubrutinib, Rituximab, Bendamustin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
SARS-CoV2, Covid19
A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults
This study is being conducted to look at the safety and immune response (how the immune system of the human body reacts) to a vaccine for SARS-CoV-2 (the virus responsible for COVID-19 infection) when administered as an…
- Trial name
- NCT04495933
- Testing
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
- Where
- Australia
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Lymphoma
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00060385
- Testing
- CHOP regimen, EPOCH regimen, cyclophosphamide
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cognitive Decline, Mild, Cognition Disorders in Old Age
Effects of Wearable Sensor-based Interactive Cognitive-motor Training in Older Adults.
Based on research showing that cognitive-motor training programs help improve cognition in older adults with mild cognitive impairment, this program uses an interactive system to combine cognitive training with exercise.
- Conditions
- Cognitive Decline, Mild, Cognition Disorders in Old Age, Subjective Memory Decline
- Trial name
- NCT05983913
- Testing
- cognitive-motor training, cognition training
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Sahmyook University
Non Hodgkin Lymphoma
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A phase II trial of TisaGenlecleucel (CTL019) in Elderly Patients with First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
- Trial name
- TIGER-CTL019 (NCT04161118)
- Testing
- CTL019
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- University of Cologne
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Respiratory Disorders
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
The purpose of this study is to test two different vaccine schedules to be used for administering the investigational NTHi Mcat vaccine that will be targeting patients with chronic obstructive pulmonary disease (COPD) to prevent…
- Trial name
- NCT03443427
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 8 sites in Canada, Germany and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune System Diseases
Zoster Vaccine Response in the Frail Elderly
This study is being done to evaluate the zoster vaccine response in the nursing home elderly (80 years or older). As the immune system ages, the response to vaccines is not always as strong as in younger people.
- Trial name
- NCT01328548
- Testing
- Zostavax
- Where
- Canada
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- McMaster University
Active Idiopathic Inflammatory Myopathy, Myositis
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM).
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA (NCT05523167)
- Testing
- EFG PH20 SC, PBO
- Where
- 202 sites in United States, Argentina and 34 more
- Volunteers
- 265 people
- Sponsor
- argenx